108447-01-4

Basic information

• Product Name: 4-bromo-5-methoxy-1,2-phenylenediamine
• Synonyms: 4-bromo-5-methoxy-1,2-phenylenediamine
• CAS NO: 108447-01-4
• Molecular Weight: 217.065
• Mol File: 108447-01-4.mol

Chemical Properties

• CAS DataBase Reference: 4-bromo-5-methoxy-1,2-phenylenediamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-5-methoxy-1,2-phenylenediamine(108447-01-4)
• EPA Substance Registry System: 4-bromo-5-methoxy-1,2-phenylenediamine(108447-01-4)

Safety Data

• Hazardous Substances Data: 108447-01-4(Hazardous Substances Data)

Usage

Uses

Used in Cosmetic Industry:
4-bromo-5-methoxy-1,2-phenylenediamine is used as a colorant in hair dyes for its ability to form colored complexes with the hair's oxidation products, providing a range of shades. Its use in oxidative hair dye formulations is particularly beneficial due to its chemical properties that facilitate this coloration process.
Used in Hair Dye Production:
In the hair dye industry, 4-bromo-5-methoxy-1,2-phenylenediamine is utilized as an active ingredient for its coloring capabilities. It contributes to the formation of the desired hair color by interacting with the hair's natural components during the oxidative process.
Used for Antibacterial Properties:
Beyond its role as a colorant, 4-bromo-5-methoxy-1,2-phenylenediamine is also used for its antibacterial properties in cosmetic products. This dual functionality makes it a valuable component in the formulation of hair dyes and other products where both coloration and hygiene are important considerations.

Upstream product

• 93702-76-2 8-methoxy-7-bromo-4-phenyl-2,3-dihydro-1H-1,5-benzodiazepinone-2 
• 6943-69-7 5-bromo-4-methoxy-2-nitro-phenylamine 
• 19056-41-8 3-bromo-p-anisidine 
• 6943-73-3 N-(3-bromo-4-methoxyphenyl)acetamide 
• 16133-49-6 5-methoxy-2-nitroaniline 
• 173312-36-2 4-bromo-5-methoxy-2-nitrobenzeneamine 
• 51-66-1 4-methoxyacetanilide 
• 7357-66-6 N-(5-bromo-4-methoxy-2-nitrophenyl)acetamide 

Downstream Products

• 1008361-65-6 5-bromo-6-methoxy-1H-benzo[d]imidazole 

Relevant articles and documents

METHODS AND COMPOSITIONS FOR MODULATING SPLICING

Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

Heterocyclic compound used as MNK inhibitor

The invention relates to a heterocyclic compound, a pharmaceutical composition containing the heterocyclic compound, a preparation method thereof, and application thereof used as a mitogen activated protein kinase interacting kinase 1 and 2-MNK1/MNK2 inhibitor. The inhibitor is the heterocyclic compound as shown in the formula (I), or its pharmaceutically acceptable salt, prodrug, solvent compound, polycrystal, isomer, stable isotope derivative or a pharmaceutical composition containing the heterocyclic compound. The compound of the invention can be used for treating or preventing MNK-mediatedrelated diseases, such as cancers.

HETEROCYCLIC KINASE INHIBITORS

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

HETEROCYCLIC COMPOUNDS AND USE THEREOF AS MODULATORS OF TYPE III RECEPTOR TYROSINE KINASES

Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFRβ kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

EP4 antagonist dihydrobenzo imidazolecarboxylic deriv. new

The present invention relates to novel benzimidazole derivatives of the general formula (I), processes for their preparation and their use for the production of pharmaceutical compositions for the treatment of diseases and indications that are connected w

Heterocyclic topoisomerase poisons

The invention provides a topoisomerase poison of formula I: wherein R1-R8 have any of the meanings defined in the specification, or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising a compound of formula I or a salt thereof, intermediates useful for preparing a compound of formula I, and therapeutic methods comprising administering a compound of formula I or a salt thereof.

Topoisomerase I inhibition and cytotoxicity of 5-bromo- and 5-phenylterbenzimidazoles

Topoisomerase I is an enzyme that is essential for maintaining the three-dimensional structure of DNA during the processes of transcription, translation and mitosis. With the introduction of new clinical agents that are effective in poisoning topoisomeras

Heterocyclic Systems Containing Bridgehead Nitrogen Atom: Part LIV - Synthesis of Thiazolobenzimidazol-3-(2H)-ones

3-Bromo-4-methoxyacetanilide (V) on nitration with fuming nitric acid in the presence of acetic anhydride gives 3-bromo-4-methoxy-6-nitroacetanilide (VI) which on hydrolysis and subsequent reduction of the nitroaniline (IX) followed by the treatment of th

BROMINATION OF 8R-4-PHENYL-2,3-DIHYDRO-1H-1,5-BENZODIAZEPINONES-2

The influence of the nature of the substituents and the brominating agent on the direction of the bromination of 8R-4-phenyl-2,3-dihydro-1H-1,5-benzodiazepinones-2 containing various substituents in annelated benzene ring.